OPC-31 |
OPC-14597 |
ARIPIPRAZOLE |
ABILIFY MAINTENA |
ABILIFY MYCITE KIT |
ABILIFY MAINTENA KIT |
ABILIFY |
ARIPIPREX |
OPC 14597 |
ABILITAT |
OPC 31 |
ARIPIPRAZOL |
ARIPIPRAZOLUM |
pubchem.compound:60795 |
chembl:CHEMBL1112 |
rxcui:89013 |
drugbank:01238 |
chemidplus:129722-12-9 |
Drug Class | antipsychotic agents |
Year of Approval | 2002 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antipsychotic agent |
Drug Categories | adrenergic alpha-1 receptor antagonists |
Drug Categories | adrenergic alpha-antagonists |
Drug Categories | adrenergic antagonists |
Drug Categories | agents producing tachycardia |
Drug Categories | agents that produce hypertension |
Drug Categories | anticholinergic agents |
Drug Categories | antidepressive agents |
Drug Categories | aripiprazole and prodrugs |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | dopamine agents |
Drug Categories | dopamine agonists |
Drug Categories | dopamine antagonists |
Drug Categories | dopamine d2 receptor antagonists |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | histamine antagonists |
Drug Categories | histamine h1 antagonists |
Drug Categories | muscarinic antagonists |
Drug Categories | neurotoxic agents |
Drug Categories | neurotransmitter agents |
Drug Categories | potential qtc-prolonging agents |
Drug Categories | qtc prolonging agents |
Drug Categories | qtc shortening agents |
Drug Categories | serotonergic drugs shown to increase risk of serotonin syndrome |
Drug Categories | serotonin 5-ht1 receptor agonists |
Drug Categories | serotonin 5-ht1 receptor antagonists |
Drug Categories | serotonin 5-ht2 receptor antagonists |
Drug Categories | serotonin agents |
Drug Categories | serotonin receptor agonists |
Drug Categories | serotonin receptor antagonists |
partial agonist (activating) |
agonist (activating) |
antagonist (inhibitory) |
Details of the Assay for Interaction | Measuring cAMP production via the Gi-coupled signaling pathway |
Direct Interaction? | True |
Endogenous Drug? | False |
partial agonist (activating) |
agonist (activating) |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serotonin 1a (5-HT1a) receptor partial agonist |
Trial Name | Abilify |
ligand |
agonist (activating) |
antagonist (inhibitory) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
ligand |
agonist (activating) |
antagonist (inhibitory) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
partial agonist (activating) |
agonist (activating) |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serotonin 2a (5-HT2a) receptor antagonist |
Specific Action of the Ligand | Partial agonist |
partial agonist (activating) |
agonist (activating) |
antagonist (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Partial agonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
ARIPIPRAZOLE | DrugBank Drug Name |
129722-12-9 | CAS Number |
Abilify | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
ARIPIPRAZOLE | Primary Drug Name |
Year of Approval | 2002 |
Drug Class | antipsychotic agents |
Drug Indications | antipsychotic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
ARIPIPRAZOLE | GuideToPharmacology Ligand Name |
D0H3HM | TTD Drug ID |